April 16, 2018
Nordic Nanovector Presents Preclinical Data at AACR 2018
Media
April 12, 2018
Targovax strengthens Board of Directors with the appointment of Catherine Wheeler
April 12, 2018
First patient starts treatment in Oncopeptides’ Phase I / II ANCHOR study with Ygalo®
April 12, 2018
Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
April 11, 2018
Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion
April 04, 2018
Nordic Nanovector provides update on the PARADIGME clinical trial
April 04, 2018
Nordic Nanovector announces that Luigi Costa will step down as Chief Executive Officer
April 03, 2018
GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)
April 02, 2018
Strongbridge Biopharma plc Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
March 28, 2018
Preliminary long-term data for WTX101 in Wilson Disease accepted as a late-breaker presentation at EASL Annual Meeting
